Biocept to host key opinion leader webinar on april 8 to discuss its csf assay for the diagnosis of cancer involving the central nervous system

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the use of the company's proprietary cerebrospinal fluid (csf) assay for diagnosing and managing tumors that have metastasized to the central nervous system (cns), including the brain or spinal column. biocept's csf assay provides enhanced sensitivity compared with csf cytology, the current standard
BIOC Ratings Summary
BIOC Quant Ranking